​How  Werfen is driving innovation in immunoassays 

Innovation stands as one of our strategic and fundamental pillars, permeating every level of our company. We continuously innovate across biomaterials, assays, and biotechnology manufacturing processes. Our goal is to enhance our expertise in immunoassays and technological capabilities, ultimately increasing efficiency and robustness, reducing time to market, and streamlining operations.

Within Werfen culture, we embrace, promote, and leverage a distinctive network comprising scientists, entrepreneurs, and key players in the IVD sector. This network enables us to identify and integrate the most cutting-edge tools and technologies. 

Looking for innovative approaches to move your immunoassay portfolio one step beyond

The selection of the primary raw material, whether an antigen, protein, or antibody, is crucial for the performance of a new immunoassay. In many cases, first-generation immunoassays have successfully utilized native proteins, demonstrating their effectiveness in delivering the desired performance for IVD products. However, working with native proteins and antigens presents inherent challenges, including significant lot-to-lot variability. Additionally, the production of these native materials is often expensive, time-consuming, and labor-intensive. As we advance in the development of more efficient immunoassays, addressing these challenges is essential to ensure consistency and reliability in diagnostic outcomes.